The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva Group, Aurobindo Pharma and RMZ. The company is looking to sell it as part of a broader land monetisation strategy.
AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 crore
